Anti-Snoring Devices

In addition to natural solutions and lifestyle changes recommended for reducing snoring, some snoring aids might be beneficial in addressing the issue. Local drug stores and pharmacies carry several over-the-counter (OTC) non-invasive products and devices that claim to offer solutions, including:

  • Nasal strips to target snoring that stems from nasal congestion;
  • Snoring mouthpieces that claim to align the jaw in a forward position to keep the back of the throat open;
  • Nasal sprays that lubricate the nasal passage that promise to help reduce snoring;
  • Anti-snoring pillows that promote sleep positions to help minimize snoring;
  • Chinstraps that keep the jaw in a closed position to help prevent snoring;
  • EPAP (Expiratory Positive Airway Pressure) technology that uses the individual’s breathing to create back pressure that opens the nasal airway and reduces vibration from the soft tissue in the back of the throat and therefore reduces or eliminates associated snoring sounds.

As the best documented of the solutions mentioned above the remainder of this discussion will focus on EPAP technology.

EPAP Technology – Clinically Proven

The EPAP technology in Theravent is based on the EPAP technology used in the prescription medical device, ProventÆ which was cleared by FDA for the treatment of sleep apnea. 

Both obstructive sleep apnea (OSA) and snoring are present on the continuum of sleep disturbances and are caused by similar anatomic factors. Because of that connection, OSA serves as an appropriate clinical model for measuring (assessing) the reduction of snoring in clinical studies.  Multiple clinical studies of EPAP technology, which comprises a single-use Microvalve placed over the opening of the nostrils have shown EPAP to be effective in addressing sleep apnea and snoring. A study published in the Journal of Clinical Sleep Medicine evaluated the long-term use of EPAP in patients with obstructive sleep apnea (OSA) and snoring. The authors of the study report that use of EPAP reduced snoring over the 12 months of treatment period1. Data show a 74.4% reduction in sleep time spent snoring; 89.3% of participants successfully wore the device for the entire night and no serious device-related events were reported.

The clinical study confirms results from two earlier studies that found prescription Provent EPAP therapy effective in treating OSA and snoring3,4.

Based upon the EPAP technology used in Provent sleep apnea therapy, Theravent® created an Anti-Snore Therapy device for over the counter consumer use. It is clinically shown to reduce snoring using the power of the user’s expiratory breathing to help keep nasal airways open and free of obstruction.5 Theravent’s patented Microvalve design creates expiratory positive airway pressure inside the nasal airway, keeping it open until the start of the next inhalation. In 2012, the FDA cleared Theravent to treat primary snoring.

Theravent offers an effective and affordable snoring solution that is readily available at retailers across the U.S. and online. Theravent comes in three  different product strengths to address the needs of different snorers.

The STARTER strength is designed to help the snorer acclimate to the use of the technology while REGULAR  and MAX offer graduating resistance levels for those with varying snoring habits. Theravent offers a trial pack to help users discover the most appropriate resistance level for their needs.


1. Kryger MH, Berry RB, Massie CA. “Long-term use of a nasal expiratory positive airway pressure (EPAP) device as a treatment for obstructive sleep apnea (OSA).”

J Clin Sleep Med 2011;7(5):449-453. DOI: 10.5664/JCSM.1304

2. Riaz M, Certal V, Nigram G, et al. “Nasal Expiratory Positive Airway Pressure Devices (Provent) for OSA: A Systematic Review and Meta-Analysis.” Sleep Disorders 2015; Article ID 734798, 15 pages.

3. Berry RB,Kryger MH, Massie CA. “A Novel Nasal Expiratory Positive Airway Pressure (EPAP) Device for the Treatment of Obstructive Sleep Apnea: A Randomized Controlled Trial.” Sleep 2011; 34(4): 479-485F.